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ABSTRACT
Specific Inhibition of the Distribution of 
Lobeglitazone to the Liver by Atorvastatin in 
Rats: Evidence for an rOATP1B2-Mediated 
Interaction in Hepatic Transport
Chang-Soon Yim
Department of Pharmaceutical Science
College of Pharmacy
The Graduate School
Seoul National University
CYP (cytochrome P450) enzymes and hOATP1B1 (organic anion transporting 
polypeptide 1B1) are reported to be involved in the pharmacokinetics of
lobeglitazone (LB), a new PPARγ agonist. Atorvastatin (ATV), a substrate for 
CYP3A and hOATP1B1, is likely to be co-administered with LB in patients 
with the metabolic syndrome. We report herein on a study of potential 
interactions between LB and ATV in rats. When LB was IV (intravenous)-
administered with ATV, the systemic clearance (CL; 2.67 ± 0.63 mL/min/kg) 
and volume of distribution at steady-state (Vss; 289 ± 20 mL/kg) for LB 
II
remained unchanged, compared to those of LB without ATV (CL, 2.34 ± 0.37 
mL/min/kg; Vss, 271 ± 20 mL/kg). While the Kp of LB was not affected by 
ATV in most major tissues, the liver Kp for LB was decreased by the co-
administration of ATV. The liver Kp values at the steady state for three levels 
of LB were significantly decreased as the result of the co-administration of 
ATV. LB uptake was inhibited by ATV in rOATP1B2-overexpressing MDCK
(Madin–Darby canine kidney) cells and in isolated rat hepatocytes in vitro. 
After incorporating the kinetic parameters for the in vitro studies into a PBPK
(physiologically based pharmacokinetics) model, the characteristics of LB 
distribution to the liver were consistent with the findings of the in vivo study.
It thus appears that the distribution of LB to the liver is mediated by the 
hepatic uptake of transporters such as rOATP1B2, and the carrier-mediated 
transport is involved in the liver specific DDI (drug-drug interaction) between 
LB and ATV in vivo.
Keywords: Lobeglitazone; Atorvastatin; Pharmacokinetics; Metabolism;
rOATP1B2; Drug-drug interactions; Physiologically based pharmacokinetics; 
Modeling; Simulation.
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1. Introduction
LB, an agonist for PPARγ, is approved in Korea for the treatment of T2DM. 
Previous studies (Sauerberg et al., 2003; Kim et al., 2004; Lee et al., 2005)
indicate that LB has a therapeutic advantage over rosiglitazone and 
pioglitazone (i.e., clinically approved/used PPARγ agonists with similar 
structural motifs) in terms of potency for the PPARγ receptor. As a result, an 
improvement in insulin sensitivity is expected even at a lower dosage (e.g., 
0.5 mg/day): The lower dosage of LB is likely to reduce the incidence of 
adverse effects (Kim et al., 2014).
We previously demonstrated that LB was primarily metabolized by 
major CYP enzymes, namely CYP 1A2, 2Cs, and 3A4 (Lee et al., 2015a; Lee 
et al., 2015b), and interacts with the human organic anion transporting 
polypeptide 1B1 (hOATP1B1) with an IC50 value of 2.44 μM (Lee et al., 
2015b). This suggests that drug-drug interactions (DDIs) are possible for LB 
in drug metabolism as well as in its distribution to tissues. Clinical 
pharmacokinetics studies of LB with other prescription drugs such as warfarin 
or amlodipine were recently conducted in Korea, without significant 
differences in the systemic pharmacokinetics of LB being reported after co-
administration (Jung et al., 2015; Kim et al., 2015). These studies were 
designed to study potential changes in the systemic pharmacokinetics of LB 
when these drugs were co-administered, considering the fact that they are 
known to share some of the same metabolic pathways of LB (i.e., CYP 1A2, 
2C9, and 3A4 with warfarin; CYP3A4 with amlodipine) (Kaminsky and Zha
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ng, 1997; Guengerich et al., 1991). The lack of appreciable differences in 
the pharmacokinetics indicates that DDI mediated by drug metabolism is less 
likely for LB.
In addition to DDI caused by the complications in drug metabolism, 
based on the literature, it is quite clear that DDIs are possible as a result of 
interactions at the level of drug transporters. For example, it was reported that 
cyclosporine inhibits the transport of rosuvastatin to the liver, probably 
mediated by hOATP1B1, thereby increasing the plasma level of rosuvastatin 
by 7.1-fold (Simonson et al., 2004). Interestingly, however, evidence for 
interactions caused by drug transporters may be less obvious and would be 
difficult to detect in some cases. For example, it was reported that the 
concentrations of metformin in the liver and kidney are elevated after the co-
administration of cimetidine or pyrimethamine probably caused by inhibiting 
mMATE1 expressed in the liver and kidney of mice (Ito et al., 2012; Shingaki 
et al., 2015) without any apparent indication of DDI in the systemic 
pharmacokinetics. It has also been noted that, the concentration for 
ciprofloxacin in the liver was decreased after the co-administration of 24-nor-
ursodeoxycholic acid by inducing the expression of mMRP4 in the basolateral 
side of the mouse liver (Wanek et  a l . ,  2016) , while the systemic 
pharmacokinetics remained unchanged. These results indicate that 
conventional methods for detecting DDI are not adequate for some 
interactions involving transporters and that the possibility of DDI needs to be 
examined in the target tissue. For the case of LB, however, the possibility of 
transporter-mediated DDI is not known.
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ATV, one of the most frequently prescribed statins (Hsyu et al., 200
1; Laufs et al., 2016), is reported to be metabolized by CYP3A4 (Park et al., 
2008), and is transported by hOATP1B1 and hOATP1B3 (Knauer et al., 2010). 
It is now well established that hyperlipidemia can occur simultaneously with 
T2DM (Iglay et al., 2016) and, thus, a combined treatment involving statins 
and hypoglycemic agents, such as LB, may become necessary clinically (Gu 
et al., 2010). It is noteworthy that ATV and LB share similar pathways for 
drug metabolism (CYP3A4) and distribution to tissues (hOATP1B1). 
Unfortunately, however, the possibility of DDI between ATV and LB does not 
appear to have been examined.
The objective of this study, therefore, was to determine whether or not 
DDIs between LB and ATV occur in rats. We were particularly interested in 
the possibility of DDI at the level of metabolism by CYP3A and the carrier-
mediated transport via rOATP1B2 (i.e., ortholog of hOATP1B1 and 
hOATP1B3) (Hagenbuch and Meier, 2004) in the pharmacokinetics of LB in 
the absence or presence of ATV co-administration. The findings indicate that, 
while no apparent interaction between LB and ATV in their systemic 
pharmacokinetics was found, a significant interaction for the hepatic 
distribution of LB was found, most likely at the level of the hepatic 
distribution via rOap1b2, after the co-administration of ATV.
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2. Materials and Methods
2.1. Chemicals and Reagents
LB (98.5% purity) was kindly provided by Chong Kun Dang Pharmaceuticals
(Seoul, Korea). ATV (98% purity) was purchased from Tokyo Chemical 
Industry (Tokyo, Japan). Glipizide (96% purity), bicinchoninic acid (BCA), 
bovine serum albumin (BSA), Hanks’ balanced salts, sodium bicarbonate, 
HEPES, and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich 
(St. Louis, MO). [3H]-Inulin (194 mCi/g) and [3H]-estradiol-17β-D-
Glucuronide (specific activity 41.4 Ci/mmol) [both from American 
Radiolabeled Chemicals (St. Louis, MO)] were also used in this study. SDS 
and polyethylene glycol 400 were purchased from Georgiachem (Norcross, 
GA) and Duksan Pure Chemicals (Ansan, Korea), respectively. Dulbecco’s 
modified Eagle’s medium, the non-essential amino acid solution, Dulbecco’s 
phosphate buffered saline (DPBS), penicillin/streptomycin, and fatal bovine 
serum were obtained from Welgene (Daegu, Korea). High-performance liquid 
chromatography grade acetonitrile (ACN) and formic acid were purchased 
from Fisher Scientific (Pittsburgh, PA) and Fluka (Cambridge, MA), 
respectively. An ammonium formate solution [5 M; Agilent Technologies 
(Santa Clara, CA)] was also used. Pooled male rat liver microsomes and the 
NADPH-regenerating system solution were purchased from Corning Gentest 
(Woburn, MA). Zoletil 50® (tiletamine-HCl/zolazepam-HCl) was purchased
from Virbac Laboratories (Carros, France) and Rompun® (xylazine-HCl) from 
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Bayer Corp. (Shawnee Mission, KS). All other chemicals were of reagent 
grade or greater and were used without further purification.
2.2. Animals
Male Sprague-Dawley (SD) rats (body weight 240-270 g) (Orient Bio Inc., 
Seongnam, Korea) were used in all in vivo / hepatocyte isolation studies. 
Experimental protocols involving the animals used in this study were 
reviewed and approved by Seoul National University Institutional Animal 
Care and Use Committee, according to the National Institutes of Health 
Publication Number 85-23 Principles of Laboratory Animal Care revised in 
1985.
2.3. IV bolus administration study for the identification of 
systemic DDIs in rats
Overnight fasted male SD rats were anesthetized by an intramuscular 
administration of 50 mg/kg of tiletamine-HCl/zolazepam-HCl (Zoletil 50®) 
and 10 mg/kg of xylazine-HCl (Rompun®). After confirming the induction of 
anesthesia, the femoral artery (for collecting blood samples) and vein (for 
administering and supplementing body fluids) were catheterized with 
polyethylene tubing (PE 50; Clay Adams, Parsippany, NJ), filled with 
heparinized saline (20 U/mL; for arterial cannulae) and normal saline (for a 
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venous cannulae), respectively. Upon recovery from the anesthesia, four types 
of dosing solutions (i.e., LB 0.5 mg/mL, LB 0.5 mg/mL with ATV 2.5 mg/mL, 
ATV 2.5 mg/mL, or ATV 2.5 mg/mL with LB 0.5 mg/mL) were prepared 
immediately prior to the administration and given intravenously to rats by a 
bolus injection. The vehicle for the dosing solutions consisted of DMSO /
polyethylene glycol 400 / saline (0.5:4:5.5, v/v/v) and the injection volume 
was 2 mL/kg. Blood samples (150 μL for each sample) were collected from 
the arterial catheter at 0, 5, 15, 30, 60, 120, 240, 360, and 480 min (for the 
study of LB pharmacokinetics) or at 0, 5, 15, 30, 60, and 120 min (for the 
study of ATV pharmacokinetics) after the administration. Immediately after 
the blood collection, an identical volume of saline to the volume of the blood 
sample was given to the animal to compensate for fluid loss. The plasma 
fraction was separated from blood samples by centrifugation (16,100 g for 5 
min at 4°C) and stored at -80°C until used in a liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) assay for LB and ATV (see below).
2.4. IV bolus administration study for the identification of 
DDIs in rat tissues
Overnight fasted male SD rats were anesthetized and catheterized as described 
above. Upon recovery from the anesthesia, four types of dosing solution
s (i.e., LB 0.5 mg/mL, LB 0.5 mg/mL with ATV 2.5 mg/mL, ATV 2.5 
mg/mL, or ATV 2.5 mg/mL with LB 0.5 mg/mL) were similarly prepar
ed and intravenously administered to rats by a bolus injection. The animals 
7
were sacrificed at 30, 60, 120, or 240 min after the administration, and tissue 
(i.e., lungs, adipose, brain, heart, kidneys, muscle, liver, spleen, and gut) 
samples were collected. In this study, samples of trunk blood were also 
collected. After tissue isolation, the samples were washed four times with ice-
cold DPBS and weighed. Twice the volume of the tissue weight of DPBS was 
then added for homogenization [Ultra Turrax homogenizer (IKA, Staufen, 
Germany)]. The mixture was then stored at -80°C until used in determinin
g the concentration of LB and ATV.
When it was necessary to determine the volume of trapped blood in 
tissue samples, rats were intravenously injected with a solution of inulin 
containing a trace amount of [3H]-inulin in normal saline (injection volume: 1 
mL/kg). Blood samples were collected at 0.5 min, the animals immediately 
sacrificed by cervical dislocation and tissue samples collected. Blood samples 
were then centrifuged at 10,770 g for 10 min and the supernatant collected. 
For tissue samples, approximately 100 mg of tissue sample was weighed and 
digested with 2 mL of soluene-350 (Perkin-Elmer Life and Analytical 
Sciences, Waltham, MA). Hydrogen peroxide (200 μL) (35%, Junsei 
Chemical, Japan) was then added and the resulting sample incubated 
overnight at room temperature to prevent quenching (Saito et al., 2001). 
Aliquots of plasma (50 μL) or tissue sample were mixed with Ultima Gold
(Perkin-Elmer), and the radioactivity of the sample was determined by liquid 
scintillation counting (Tri-Carb 3110TR Liquid Scintillation Analyzer, Perkin-
Elmer). Considering the possibility that inulin might not be distributed to 
erythrocytes (Gaudino and Levitt, 1949), the estimated trapped plasma 
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volume was subsequently divided by 0.55 (i.e., 1-hematocrit). In all 
subsequent studies where a tissue concentration of drugs was reported, the 
concentration found in the sample was corrected by subtracting the portion in 
the trapped blood volume.
2.5. IV Infusion study of LB with and without ATV in rats
When it was necessary to further determine the distribution of LB to the liver, 
a constant LB concentration in the plasma was achieved by IV infusion and 
the liver concentration determined in the absence and presence of the co-
administration of ATV. Thus, overnight fasted male SD rats, weighing 240-
270 g, were anesthetized and catheterized, as described above. After 
recovering from the anesthesia, LB was intravenously infused to rats at the 
rate of 50, 250, or 1000 ng/min along with or without ATV solution [10 μg/10 
μL/min; DMSO / polyethylene glycol 400 / saline (0.5:2:7.5, v/v/v)] using an 
infusion pump (Harvard, Holliston, MA). Blood samples (150 μL) were 
collected from the catheter connected to the artery at 30, 60, 120, 240, 300, 
and 360 min. Upon collecting the last blood sample, the animals were 
sacrificed and a liver sample collected. The plasma and liver samples were 
processed for analysis as described above.
2.6. Determination of blood-to-plasma concentration ratio 
and plasma protein binding of LB
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LB was added to fresh blank blood at final concentrations of 0.1, 1, or 10 μM, 
and the mixture incubated at 37°C in a water bath for 60 min. After the 
incubation, the mixture was centrifuged (16,100 g) and the plasma was 
collected as the supernatant: The concentration of LB was then determined by 
LC-MS/MS analysis to calculate blood-to-plasma concentration ratio.
In this study, the extent of plasma protein binding was also 
determined for LB by the rapid equilibrium dialysis method, according to the 
manufacturer’s recommended protocol (Thermo Fisher Scientific, Waltham, 
MA). Briefly, the plate of the dialysis device was rinsed with 20% ethanol for 
10 min. LB [0.1, 0.3, 1, 3, or 10 μM as the final concentration for the rat 
plasma, 0.5, 5, or 50 μM for rat liver microsomes (see below), 0.5, 1, 2, 5, 10, 
or 20 μM for 5 μM BSA (see below) in the transport medium (9.7 g/L Hanks’ 
balanced salts, 2.38 g/L HEPES, and 0.35 g/L sodium bicarbonate, pH 
adjusted to 7.4)] and ATV (final concentration; 0.1, 1, or 10 μM for 5 μM 
BSA in the transport medium) were added to the medium (i.e., the plasma, the 
microsomal incubation medium, or the transport medium). Aliquots of the 
mixture (200 μL) and protein free solution (350 μL) were placed into the 
sample chamber and the buffer chamber, respectively, and the device was 
sealed / incubated on a shaker (150 rpm) at 37°C for 4 h. After the completion 
of the incubation, an aliquot (50 μL) was collected from each side of the 
chamber. To make sure that the matrix of the samples matched, a 50 μL 
aliquot of blank medium was then added to the protein free solution sample, 
and an equal volume of protein free solution was also added to the medium. 
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The resulting sample was then analyzed for LB and ATV to determine the 
unbound fraction (fu). In this study, the recovery was found to be between 70% 
and 100% in all experiments.
2.7. Stability of LB in rat liver microsomes
In this study, the metabolic stability of LB with or without ATV in rat liver 
microsomes was determined. The reaction mixture (total volume of 1 mL) 
consisted of a NADPH-regenerating solution containing 1.3 mM NADP+, 3.3 
mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenase, and 
3.3 mM MgCl2 as recommended by the manufacturer’s protocol. Depending 
on the study, an aqueous solution [100 mM potassium phosphate buffer (pH 
7.4)] containing LB (final concentration in the reaction mixture; 1, 2, 5, 10, 20, 
or 50 μM) without ATV, or LB (the final concentration; 5 μM) with ATV (the 
final concentration; 1, 5, 10, 20, 50, 100, or 200 μM) was also added. The 
concentration of organic solvent (i.e., DMSO) in the incubation mixture was 
maintained at under 1% to limit its influence on microsomal enzymes. After 
pre-incubation (37°C for 10 min), the reaction was initiated by the addition of 
rat liver microsomes (50 μL; the final microsomal protein concentration at 0.5 
mg/mL). Preliminary experiments were carried out to determine the 
incubation time for the given LB concentrations for a linear rate of LB 
disappearance (data not shown). Samples were collected (50 µL) at various 
pre-determined times and the samples were then added with an ice-cold ACN 
solution (i.e., for the termination of the reaction) containing glipizide (100 
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ng/mL, internal standard). The concentration of LB in the mixture was 
determined by LC-MS/MS assay.
2.8. rOATP1B2 cloning
The protein coding region of rOATP1B2 (Genbank accession 
number NM_031650.3) was cloned from a rat total liver mRNA library 
(Takara Shuzo, Japan). The RNA (1 μg) was reverse transcribed using 
Primescript 1st strand cDNA Synthesis Kit (Takara) by incubating the mixture 
at 65°C for 5 min, cooling to 4°C followed by adding RNase inhibitor and 
RTase into the reaction mixture, and then the following reaction was 
performed by incubating at 42°C for 60 min, heating to 95°C for 5 min and 
cooling to 4°C. Specific primers for cloning of the rOATP1B2 coding region 
were 5′-GCTAGCAGTGATTGCAGACGTTCCCA-3′ (sense strand; NheI site 
underlined) and 5′-AAGCTTGTCCATCCTTGCCCCATTCT-3′ (antisense 
strand; HindⅢ site underlined). The polymerase chain reaction was 
performed using Ex taq DNA polymerase (Takara) using the following 
settings: 30 cycles of denaturation at 94°C for 30 sec, a primer-annealing step 
at 63°C for 30 sec, and extension at 72°C for 3 min. The amplicon was cloned 
into pcDNA5/FRT vector (Invitrogen, Carlsbad, CA), and the identity of the 
insert confirmed by sequencing. The plasmid containing the wild type form of 
rOATP1B2 was selected and transfected into Madin-Darby Canine Kidney 
II/FRT (MDCKII/FRT) cells using the FuGENE® transfection reagent. The 
transfected cells were incubated in the culture medium containing 0.1 mg/mL 
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hygromycin B (Invitrogen) for several weeks for selection. The expression of 
rOATP1B2 was confirmed by the reverse transcription polymerase chain 
reaction in the transfected cells. The functional expression was determined by 
comparing the uptake of radiolabeled estradiol-17β-glucuronide [a standard 
substrate of the transporter (Cattori et al., 2000)] in the transfected cells with 
that in mock-transfected MDCKII/FRT cells (Fig. 1). In this study, at least a 
60-fold higher uptake was found in rOATP1B2 transfected cells with 
estradiol-17β-glucuronide. Since the measurements in this study involved 
uptake across the apical membrane, this observation indicates that the 
transporter is expressed ubiquitously in the plasma membrane, rather than 
localized in the basolateral membrane (i.e., endogenous site of expression), in 
the transfected cells. Protein concentrations were determined by a BCA assay 
(Smith et al., 1985) and used for the correction of the transport function.
2.9. Uptake of LB in rOATP1B2-transfected MDCKII/FRT 
cells
To determine the kinetic characteristics of rOATP1B2 transport, 
MDCKII/FRT cells expressing the anion transporter were used. Thus, 
rOATP1B2 cells were grown in Dulbecco’s modified Eagle’s medium with 
10% (v/v) fatal bovine serum, 1% (v/v) non-essential amino acid solution, 100 
units/mL penicillin/streptomycin, and 10 mM HEPES. All cells were kept at 
37°C with 5% CO2 and 95% relative humidity. Cells were seeded in poly-L-
ornithine (Sigma-Aldrich) -coated 24-well (2.0 cm2) cell-culture plates 
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(Corning, NY) in supplemented Dulbecco’s modified Eagle’s medium at a 
density of 0.5 × 106 cells/well and then grown in a humidified atmosphere of 
5% CO2 at 37°C for 2 days. Preliminary studies were carried out with LB to 
determine the appropriate reaction time in rOATP1B2 cells as well as mock 
cells. In this study, up to 12 min of incubation, the uptake was proportional to 
the incubation time for LB (Fig. 2), and, thus, a 10 min incubation time was 
used in subsequent studies involving LB and rOATP1B2 expressing cells.
For measurement of LB transport in rOATP1B2 cells, the cells were 
first washed twice with pre-warmed DPBS and pre-incubated with transport 
medium containing 2% (final concentration) DMSO (i.e., solubilizing agent 
for LB). From a pilot experiment, it was found that DMSO up to 2% in the 
transport medium had no appreciable effect on the function of the transporter 
(Fig. 3), consistent with other literature findings (Taub et al., 2002; Da 
Violante et al., 2002). LB was prepared in DMSO and diluted with 5 μM BSA 
in transport medium (final DMSO concentration of 2%). The addition of BSA 
was found to be necessary to suppresses the nonspecific adsorption of the 
drugs on the experimental apparatus and/or cell surface (Takeuchi et al., 
2011). The uptake of LB was measured in six different concentrations ranging 
from 0.5 to 20 μM (i.e., 0.5, 1, 2, 5, 10, or 20 μM) in rOATP1B2 and in mock 
cells. After pre-incubation for 10 min at 37°C, the transport medium was 
removed and replaced with pre-warmed medium containing LB in the 
presence and the absence of ATV (200 μL). Upon completion of the 
incubation, the aqueous medium was first aspirated, the cells washed twice 
with ice-cold DPBS containing 0.1 % BSA (400 μL) and once with ice-cold 
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DPBS (400 μL). The final rinsing solution was then aspirated and 0.1 % (w/v) 
SDS added to the cell suspension for lysis. A preliminary experiment 
indicated that the addition BSA up to 3% in the rinsing solution had no effect 
on the protein concentration in the cell lysate. In addition, the effect of 
limiting the non-specific binding on the experimental apparatus and/or on cell 
surface was not statistically different for BSA concentrations ranging from 0.1% 
to 10% in the rinsing solution (Fig. 4). The resulting mixture was agitated for 
30 min, and an ACN solution containing glipizide (100 ng/mL, internal 
standard) added. After vortexing for 5 min and centrifugation for 5 min 
(16,100 g), an aliquot (50 µL) of the supernatant was collected and the 
concentration of LB in the supernatant determined by LC-MS/MS assay (see 
below). The transport rate was normalized by the protein concentration in the 
sample as determined by a BCA assay. When it was necessary, the number of 
cells was estimated using the predetermined relationship 
[  	(mg	protein mL)⁄ = 0.304 × 10  ∙  	(cells) + 0.0335 , r2 = 0.994] 
between the protein concentration (in mg protein/mL) and the number of cells 
(in 106 cells).
When the inhibitory effect of ATV on the transport function of LB in 
rOATP1B2 cells was studied, the uptake of LB (5 µM) was determined in the 
cells in the presence of various concentrations of ATV (i.e., 0, 0.01, 0.1, 1, 10, 
or 30 μM). The transport medium containing DMSO (2%, final concentration) 
was prepared and BSA (5 μM, final concentration for minimizing nonspecific 
binding) was added. After a 10 min incubation at 37°C, the uptake was 
terminated by aspiration of the transport medium. The cells were then rinsed 
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twice with ice-cold DPBS containing 0.1% BSA (400 μL) and once with ice-
cold DPBS (400 μL). Cells were lysed for 30 min in 0.1 % (w/v) SDS and the 
mixture agitated. An ACN solution containing glipizide (100 ng/mL, internal 
standard) was then added to the mixture. After vortexing for 5 min and 
centrifugation for 5 min (16,100 g), an aliquot (50 µL) of the supernatant was 
collected and the concentration of LB determined by an LC-MS/MS assay. 
The data were normalized by the protein concentration in the sample as 
determined by BCA assay. Preliminary studies were carried out, in an attempt 
to determine whether the opening of the tight junction is required for transport 
in the case of rOATP1B2 expressing cells. Therefore, the cells were pretreated 
with EDTA according to a literature report [Wang et al (2016)] with minor 
modifications. Briefly, a Ca2+/Mg2+-free transport medium containing 500 μM 
EDTA was prepared and rOATP1B2 expressing cells were pretreated for 2 h. 
The transport experiment was then performed as described above. Although
the uptake of LB was slightly increased both in mock and rOATP1B2 
expressing cells with the comparable Km and Ki values, this finding suggests 
that the kinetic properties of carrier mediated transport are not significantly 
altered for LB by EDTA pre-treatment. Therefore, we chose to exclude the 
EDTA pre-treatment step before the transport experiment to prevent the 
formation of any possible artifacts resulting from the EDTA pre-treatment.
2.10. Uptake of LB in isolated rat hepatocytes
Rat hepatocytes were isolated using the two-step collagenase perfusion 
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method with minor modifications (Kotani et al., 2011). Briefly, under anesthe
sia, a cannulae was inserted into the portal vein followed by perfusing with a 
Ca2+/Mg2+-free buffer at the flow rate of 20 mL/min for 5 min. Upon the 
initiation of the perfusion, the inferior vena cava was dissected to allow the 
perfusate to exit. When necessary, the perfusion medium was switched to a 
buffer containing 50 mM CaCl2, and 0.5 mg/mL collagenase (Sigma-Aldrich) 
at a flow rate of 20 mL/min for 10 min. Hepatocytes from the digested liver 
were dispersed in fresh perfusion buffer and separated from the connective 
tissue by filtration through a sterile 50-mesh (the size of the sieve opening of 
280 μm). Rat hepatocytes were separated from non-parenchymal cells in the 
crude hepatocyte fraction as a pellet by centrifugation at 50 g for 5 min. The 
cells were then resuspended in Krebs-Henseleit buffer (KHB) and centrifuged 
again at 50 g for 5 min. In this study, hepatocytes having a viability of greater 
than 80%, as determined by a trypan blue exclusion assay, were used in 
subsequent experiments. The resulting cell pellet was resuspended in Williams’ 
media E containing 10% (v/v) fetal bovine serum, 1% (v/v) 
penicillin/streptomycin, and 0.01% (v/v) ITS (i.e., 10 mg/mL insulin, 5.5 
mg/mL transferrin, and 5 μg/ml selenium) premix (Sigma-Aldrich) at pH 7.4. 
The hepatocytes were plated in 24-well collagen I (Sigma-Aldrich)-coated 
plates at a density of 5 × 105 viable cells per well in 0.5 mL of supplemented 
Williams’ media E. The plate was equilibrated from 5 to 6 h at 37°C in an 
atmosphere containing 5% CO2 to allow the cells to adhere to the collagen 
coated surface.
In this study, hepatocyte uptake was measured for six concentrations 
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of LB (i.e., 0.5, 1, 2, 5, 10, or 20 μM). After approximately 5-6 h of cell 
plating, the medium was aspirated, and the attached cells were rinsed twice 
with pre-warmed DPBS. LB was dissolved in KHB containing DMSO (5%, 
final concentration) and BSA (5 μM, final concentration). In a preliminary 
study, the addition of DMSO up to a final concentration of 10% did not 
appear to have an appreciable impact on transport function (Fig. 5), consistent 
with previous observations (Da Violante et al., 2002). The transport reaction 
was initiated by the addition of a KHB solution containing LB (200 μL) on 
the top of the plate. According to our study (Fig. 6), the accumulation of LB in 
the hepatocytes was proportional to the incubation time up to 2 min and this
incubation time was used in subsequent studies. Cellular uptake was 
terminated by aspiration of the transport medium, and, cells rinsed twice with 
ice-cold DPBS containing 0.1% BSA (400 μL) and followed by an additional 
washing with ice-cold DPBS (400 μL). The hepatocytes were lysed for 30 min 
by the addition of 0.1% (w/v) SDS and agitation. An ACN solution containing 
glipizide (100 ng/mL, internal standard) was then added to the lysate and the 
concentration of LB determined by a LC-MS/MS assay. When necessary, the 
transport rate was normalized by the amount of protein in the sample as 
determined by a BCA assay. The number of hepatocytes was also estimated 
using the predetermined relationship [ 	(mg	protein mL)⁄ = 0.600 × 10  ∙
 	(hepatocytes) − 0.0072, r2 = 0.998] between the protein concentration (in 
mg protein/mL) and the number of hepatocytes (in 106 hepatocytes).
For the determination of the inhibitory effect of ATV on the transport 
of LB in rat isolated hepatocytes, LB (5 µM) uptake was measured in the 
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presence of various concentrations of ATV (i.e., 0, 0.001, 0.01, 0.1, 1, 10, 30, 
or 100 μM). Thus, the medium was aspirated followed by rinsing twice with 
pre-warmed DPBS. The DPBS was then aspirated, and the cells pre-incubated 
for 60 min at 37°C with KHB containing various concentrations of ATV (i.e., 
0, 0.001, 0.01, 0.1, 1, 10, 30, or 100 μM) and BSA (5 μM, final concentration). 
After pre-incubation for 60 min (Amundsen et al., 2010; Shitara et al., 2013), 
the medium was switched to KHB containing BSA (5 μM, final concentration) 
and 5 μM of LB along with various concentrations (i.e., 0, 0.001, 0.01, 0.1, 1, 
10, 30, or 100 μM) of ATV. After incubation at 37°C for 2 min, uptake was 
terminated by aspirating the medium, followed by rinsing twice with ice-cold 
DPBS containing 0.1% BSA (400 μL) and once with ice-cold DPBS (400 μL). 
The hepatocytes were lysed for 30 min in 0.1% (w/v) SDS and the mixture 
agitated. An ACN solution containing glipizide (100 ng/mL, internal standard) 
was then added to the lysate. The concentration of LB was determined by an 
LC-MS/MS assay. When necessary, the transport rate was normalized by 
amount of protein in the sample as determined by a BCA assay.
2.11. LC-MS/MS assay for LB and ATV
The concentration of LB and ATV in rat plasma samples, tissue homogenates 
or cell lysates was determined using an LC-MS/MS assay method as 
previously described (Lee et al., 2009; Kim et al., 2012) with a minor 
modification. Briefly, an aliquot (50 μL) of sample was vortex mixed with an 
ACN solution containing glipizide (100 ng/ml, internal standard) followed by 
19
a centrifugation (16,100 g for 5 min at 4°C). An aliquot (5 µL) of the 
supernatant was directly injected onto the LC-MS/MS. In this study, the LC-
MS/MS system was equipped with a Waters e2695 high-performance LC 
system (Milford, MA) and API 3200 Qtrap mass spectrometer (Applied 
Biosystems, Foster City, CA). Mobile phase, consisting of (A) 0.1% formic 
acid in ACN and (B) 10 mM ammonium formate in purified water, was 
delivered at the flow rate of 0.3 mL/min using a gradient elution involving 30% 
of A (0 min), from 30% to 80% of A (0–0.5 min), 80% of A (0.5–1.5 min), 
from 80% to 30% of A (1.5–2 min), and 30% of A (2–5 min). The 
chromatographic separation was carried out on a reversed phase high-perform
ance LC column (Eclipse XDB-C18, 3.5 μm, 2.1 × 100 mm, Agilent 
Technologies, Santa Clara, CA) at 25°C while the temperature in the 
autosampler was maintained at 4°C during the analysis. Samples were ionized 
using a turbo ion spray interface in the positive ionization mode and 
monitored at the following Q1/Q3 transitions (m/z): 481.3/258.2 for LB, 
559.3/440.4 for ATV and 445.8/320.9 for glipizide. The common source/gas 
conditions for LB, ATV and glipizide were as follows: The pressure of the 
curtain gas, ion spray voltage, source temperature, ion source gas 1 and ion 
source gas 2 were 25 psi, 4500 V, 550°C, 60 psi and 60 psi, respectively. The 
declustering potentials for LB, ATV, and glipizide were 77.9, 45.0, and 47.5 V, 
respectively. The entrance potentials were 7.4, 4.0, and 4.0 V, collision 
energies were 47, 27, and 17 V, and the collision cell exit potentials were 4.0, 
6.0, and 8.0 V, respectively. The detector response was linear in the 
concentration range examined (i.e., 5-5000 ng/mL) for both LB and ATV in 
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the rat plasma samples with inter-/ intra-day precisions of less than 10% and 
an accuracy within 8% of the theoretical value, indicative of a valid assay for 
LB and ATV. In addition to plasma samples, the calibration curves for LB and 
ATV in the rat tissue homogenates were linear (i.e., 0.992 ≤ r2 ≤ 0.999 for LB 
and 0.995 ≤ r2 ≤ 0.999 for ATV, respectively) in the concentration range 
studied. The concentration of LB in cell lysates were also determined with the 
linear calibration curves (i.e., 0.998 ≤ r2 ≤ 0.999 in cell lysates from mock and 
rOATP1B2 cells, and 0.998 ≤ r2 ≤ 0.999 in cell lysates from isolated rat 
hepatocytes).
2.12. Data analysis
2.12.1. In vitro kinetic analysis
When it was necessary, the in vitro metabolic kinetic parameters (e.g., Km, 
Vmax, and Ki) were determined by fitting the data to eq. 1 and eq. 2 (Segel, 
1975):
  =
     ∙ [ ]
   + [ ]
(1)
  =
     ∙ [ ]
   ∙ (1 +
[ ]
  
) + [ ]
(2)
where V was the rate of metabolic reaction, Vmax the maximal rate of 
metabolism, Km the Michaelis-Menten constant, Ki the inhibition constant, [S] 
the LB concentration as a substrate, and [I] the ATV concentration as an 
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inhibitor, respectively.
In addition, the cellular transport rate (J) was estimated from the 
amount of LB uptake in cell lysates, divided by the incubation time, and
expressed in eq. 3 and eq. 4.
In the case where only passive transport was present,
  =    ∙ [ ] (3)
In case of parallel passive and carrier-mediated transports,
  =
     ∙ [ ]
   + [ ]
+    ∙ [ ]
(4)
where PS is the unbound clearance via passive diffusion and [S], Km, and Jmax
are the unbound concentration of LB, unbound Michaelis-Menten constant, 
and the maximal rate of the carrier-mediated transport, respectively. Kinetic 
parameters (e.g., PS, Km, and Jmax) were estimated by the simultaneous fitting 
of the in vitro data to eq. 3 and eq. 4 using nonlinear regression analysis. The 
measured value for uptake in mock cells may contain some statistical 
variability and the correction may not be adequate in some cases (e.g., 
resulting in a negative transport value after the correction). As indicated in the 
literature (DeLean et al., 1978), a simultaneous fitting approach may result in 
more reliable values in estimating vitro kinetic parameters. Therefore, we 
chose to use this method of kinetic analysis.
When it was necessary to analyze the kinetics of the concentration-
dependent inhibition of LB transport by ATV, eq. 5 was fitted to the in vitro 
data to estimate the half maximal inhibitory concentration (IC50). In addition, 
the Ki value was estimated using eq. 6 (Cheng and Prusoff, 1973):
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  =      − (     −   ) ∙ (
[ ]
[ ] +     
)
(5)
   =
    
(1 +
[ ]
  
)
(6)
where R, Rmax, R0, [I], [S], and Km are the ratio of the amount of LB transport 
to the value for the control group treated without ATV, the maximum value of
R, the minimum value of R, the ATV concentration, the unbound 
concentration of LB as a substrate, and unbound Michaelis-Menten constant, 
respectively. It has been reported that the adoption of Hill’s slope factor in the 
Cheng-Prusoff equation may introduce additional errors (Lazareno and 
Birdsall, 1993). Therefore, the IC50 was estimated without using Hill’s slope 
to minimize additional errors (eq. 5). The Winnonlin® Professional 5.0.1 
software (Pharsight Corporation, Mountain View, CA) was used for the 
nonlinear regression analysis using the equations described above.
2.12.2. Non-compartmental pharmacokinetic analysis
Standard non-compartmental analyses were carried out using the Winnonlin®
to calculate the pharmacokinetic parameters (Gibaldi and Perrier, 1982)
including the area under the plasma concentration–time curve from time zero 
to infinity (AUCinf), elimination clearances (CL), terminal t1/2, mean residence 
time (MRT), and apparent volume of distribution at steady state (Vss).
The tissue-to-plasma concentration ratio of LB (i.e., Kp) was 
calculated using the eq. 7 (Sawada et al., 1985) after the administration of an 
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IV bolus of LB and/or ATV to rats.
   =       ,             ,      ⁄ (7)
where AUCinf,tissue represents the area under the drug concentration–time curve 
in tissue and AUCinf,plasma represents the area under the drug concentration–
time curve in plasma after the IV bolus administration. For the calculation of 
the tissue-to-plasma partition coefficient (Kp), the contribution of trapped 
blood in the collected tissue was corrected using the volume of blood trapped 
in tissue samples.
2.12.3. PBPK modeling and simulation
In this study, a PBPK model (see Theoretical) was constructed assuming the 
simultaneous IV bolus administration for LB and ATV. The PBPK model 
consisted of 9 tissues corresponding to the different tissues of the body (lung, 
adipose, brain, heart, kidneys, muscle, liver, spleen, and gut) and the tissues 
were assumed to be connected by the circulatory system (arterial and venous
side). Physiological and anatomical variables, required in the PBPK 
calculation, were obtained from the literature (Brown et al., 1997), [i.e., 
essentially the default values found Simcyp® software (Jamei et al., 2009),
version 15 Release 1 (Simcyp Limited, Sheffield, UK)]. In this calculation, 
the rate of LB/ATV distribution to tissues, including the liver, was assumed to 
be perfusion rate-limited and the standard mass balance differential equations 
were used with minor modifications (Lee et al., 2011) (see Theoretical).
After confirming the adequacy of the constructed PBPK model (for 
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single IV bolus administration of LB and ATV, respectively) (Fig. 7) with 
Simcyp® animal simulator (version 15 Release 1), a simulation was carried 
out with Berkeley Madonna™ software (version 8.3.18; University of 
California, Berkeley, CA) since a DDI module for rats was not available in the 
Simcyp® software. In this study, the fourth order of the Runge-Kutta method 
was used for the numerical integration.
2.12.4. Statistical analysis
When it was necessary to compare the mean values between/among groups, 
the unpaired Student’s t test or one-way ANOVA, followed by Tukey’s post 
hoc test, was used. In this study, data were expressed as the mean ± S.D. and p
< 0.05 was accepted as denoting statistical significance.
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3. Results
3.1. DDI between LB and ATV in systemic and tissue 
pharmacokinetics in rats
The mean plasma concentration-time profiles are shown in Fig. 8A for an IV
bolus administration to rats at a dose of 1 mg/kg LB with or without the 
simultaneous administration of ATV at dose of 5 mg/kg: The LB 
concentration profile in the case of the co-administration of ATV was 
comparable to that without ATV (Fig. 8A). The pharmacokinetic parameters, 
as estimated from a standard moment analysis, are summarized in Table 1. 
The systemic clearance (CL) of LB with or without ATV were 2.67 ± 0.63 and 
2.34 ± 0.37 mL/min/kg, respectively, and these values were not significantly 
different from each other. The volume of distribution at steady state (Vss) for 
LB with and without ATV were 289 ± 20 and 271 ± 20 mL/kg, respectively. 
Furthermore, the secondary pharmacokinetic parameters for LB, such as 
AUCinf, t1/2, and MRT were not affected by the co-administration of ATV. 
Similar to the case of LB, the ATV concentrations in rat plasma with or 
without LB co-administration were not changed, as shown in Fig. 8B and the 
summary of pharmacokinetic parameters for ATV (Table 1). Collectively, 
these observations suggest that there is no appreciable interaction in their 
systemic pharmacokinetics when LB and ATV are simultaneously given in 
rats.
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The mean tissue concentration-time profiles for LB (Fig. 9A) and 
ATV (Fig. 9B) are depicted in Fig. 9 for an IV bolus administration to rats at 
the LB dose (i.e., 1 mg/kg) with or without the co-administration of ATV (i.e., 
5 mg/kg). The tissue-to-plasma partition coefficient (Kp) found in this study, 
along with the volume of blood trapped in tissues for LB and ATV are listed 
in Table 2. When LB was administered intravenously without ATV, the liver 
appeared to be the primary organ for distribution, consistent with our previous 
findings (Lee et al., 2015b). The estimated Kp,liver value for LB was 2.34 in the 
absence of ATV co-administration, while the value was reduced to 1.55 in the 
presence of ATV co-administration. For the case of the distribution of LB to 
tissues other than the liver, ATV co-administration did not appear to 
significantly affect the distribution of LB. For the case of ATV without LB co-
administration, the liver was found to be one of the primary organs for this 
distribution (i.e., Kp,liver = 97.8 and Kp,gut = 125). However, the Kp,liver and Kp,gut
values for ATV were reduced to 65.4 and 64.1, respectively, by the co-
administration of LB. These observations suggest that DDIs might be a 
possibility at the level of drug distribution when LB and ATV are 
simultaneously administered.
3.2. Dose dependency of the liver-to-plasma concentration 
ratio of LB in rats
In this study, different levels of LB in steady state was attained, and the 
concentrations of LB in the plasma / the liver determined, in an attempt to 
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examine the dependency of Kp,liver on LB dosage and ATV co-administration. 
The mean plasma concentration–time profiles are shown in Fig. 10A for IV 
infusions of LB to rats at rates of 50, 250, or 1000 ng/min with and without 
the simultaneous infusion of ATV at a rate of 10 μg/min. For all infusion rates, 
the concentrations of LB in the plasma for 4, 5, and 6 h of infusion were 
found to not be statistically different among the three time points for a given 
rate, confirming that a steady state had been reached by 4 h after the infusion. 
It was also noted that ATV co-administration did not result in a change in LB 
concentration in the plasma at a 6 h infusion.
The LB concentration was determined in the liver at 6 h: The liver-to-
plasma concentration ratio for LB without ATV co-administration was 3.14 ± 
0.46 (at 50 ng/min), 1.55 ± 0.52 (at 250 ng/min), and 0.959 ± 0.259 (at 1000 
ng/min) (i.e., p < 0.001 by one-way ANOVA), respectively. In addition, the 
liver-to-plasma concentration ratio for LB with ATV co-administration was
1.38 ± 0.39 (at 50 ng/min), 0.701 ± 0.013 (at 250 ng/min), and 0.714 ± 0.184 
(at 1000 ng/min), respectively, indicating that the co-administration of ATV 
significantly decreases the liver-to-plasma concentration ratio for LB (Fig. 
10B). For the case of a 1000 ng/min LB infusion condition, the liver-to-
plasma concentration ratio for LB was not further decreased by ATV, probably 
because the transport of LB would be fully saturated by the high concentration 
of LB. Collectively, these observations indicate that the distribution of LB to 
the liver is mediated by saturable transport process(es) and that transport to 
the liver is inhibited by ATV in rats.
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3.3. Blood-to-plasma concentration ratio (B/P) and plasma 
protein binding
The B/P of LB were 0.631 ± 0.023, 0.611 ± 0.022, and 0.667 ± 0.077 (i.e., no 
statistical difference, by one-way ANOVA) at concentrations of 0.1, 1, and 10 
μM, respectively. Considering the lack of concentration dependency in the 
distribution to blood cells, the average B/P for LB (i.e., 0.636) for the three 
concentrations was assumed to be representative and the value was used in 
subsequent calculations.
The fraction of unbound LB in the rat plasma (fu,plasma) was also 
found to be independent in the LB concentration range from 0.3 to 10 μM. 
The representative (i.e., averaged) fu,plasma value of LB was then calculated as 
0.00267 ± 0.00036. The fraction of unbound LB in the microsomal incubation 
medium (fu,MIC) was found to be independent in the concentration range from 
0.5 to 50 μM, and the representative fu,MIC value of LB was estimated to be 
0.479 ± 0.063. However, the unbound fraction of LB at 5 μM BSA in the 
transport medium (fu,BSA) increased with increasing LB concentration in the 
range from 0.5 to 20 μM (i.e., approximately 0.111-0.447). For the case of 
fu,BSA of ATV at 5 μM BSA in the transport medium was found to be 
independent in the concentration range  from 1 to 100 μM, and the 
representative value for fu,BSA was estimated to be 0.588 ± 0.045. These values 
were used in subsequent calculations.
3.4. Stability of LB in the presence and absence of ATV in rat 
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liver microsomes
The concentration-metabolic reaction rate profile for LB in rat liver 
microsomes is shown in Fig. 11A. The Eadie-Hofstee transformation of the 
data is also presented as an inset in Fig. 11A. In general, the metabolic rate 
decreased proportionally with increasing V/[LB] value, suggesting that a 
saturable process is involved in the metabolic reaction. As a result, assuming
that simple Michaelis-Menten kinetics is involved as shown in eq. 1, a 
nonlinear regression analysis indicates that the Km,MIC and Vmax,MIC values are 
4.37 ± 0.90 μM and 996 ± 110 nmole/min/mg protein, respectively. The 
inhibitory effect of ATV on the metabolic reaction rate of LB in rat liver 
microsomes was also determined (Fig. 11B) in this study. Based on a 
nonlinear regression analysis using eq. 2, the Ki,MIC value was estimated to be 
27.0 ± 5.7 μM. Using the kinetic characteristics obtained in this study, the 
estimated extraction ratio was calculated to be 0.03 for LB. Therefore, we 
assumed that a correction of Kp,liver for LB was not necessary and this value is 
reported without correction.
3.5. Uptake of LB in rOATP1B2-transfected MDCK cells and 
isolated rat hepatocytes
The unbound concentration-uptake rate profile for LB in mock cells and 
rOATP1B2-cells are shown in Fig. 12A. Since both LB and ATV drugs that 
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highly bind to plasma proteins (i.e., fu,plasma values of 0.00267 for LB and 
0.0567 for ATV, respectively), it is possible that they might also bind non-
specifically to the surfaces of experimental apparatus, thereby causing 
experimental artifacts. In this study, we chose to include BSA in the 
incubation medium and washing buffer to prevent / minimize non-specific 
binding to the experimental apparatus and/or cell surface (Takeuchi et al., 
2011). As a result, the fu,BSA values of LB were multiplied by the total LB 
concentration to estimate the concentration of unbound LB in the transport 
medium. Using this experimental design and a nonlinear regression analysis, 
Km,OATP and Jmax,OATP values were found to be 2.06 ± 0.45 μM and 2.42 ± 1.27 
pmol/min/106 cells, respectively (eqs. 3 and 4).
The profile for the unbound concentration-uptake rate for LB in rat 
hepatocytes is shown in Fig. 12B. Similar to the case of transfected cells, the 
PS, Km,hepa, and Jmax,hepa values were estimated to be 21.0 ± 6.0 µL/min/10
6
cells, 16.3 ± 10.0 μM, and 637 ± 384 pmol/min/106 cells, respectively, (eqs. 3 
and 4) based on a nonlinear regression analysis. From the inhibitory effect of 
ATV on the transport rate of LB in rOATP1B2 cells (Fig. 12C) and rat 
hepatocytes (Fig. 12D), a nonlinear regression analysis indicated that the 
IC50,OATP and IC50,hepa are 0.473 ± 0.278 and 0.984 ± 0.812 μM, respectively. 
Based on the relationship given by Cheng and Prusoff (Cheng and Prusoff, 
1973), the Ki,OATP and Ki,hepa values were estimated to be 0.296 ± 0.174 and 
0.875 ± 0.739 μM by eq. 6.
3.6. Simulation of LB pharmacokinetic after single IV dose 
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and DDIs using PBPK model
In this study, we attempted to use a PBPK model to predict the plasma and 
tissue kinetics of LB at a dose of 1 mg/kg (Fig. 9A) using primarily in vitro 
experimental results (Table 3). Our calculations indicate that the profiles for 
the plasma and liver concentration can be reasonably predicted when LB was 
given to rats intravenously without the co-administration of ATV. (Figs. 13A 
and 13B). Accordingly, the ratios of AUCplasma to the AUCliver (i.e., Kp,liver) 
were calculated to be 2.18 ± 0.09 (Table 4) from in vitro data (i.e., Km,MIC, 
Vmax,MIC, PS, Km,hepa, and Jmax,hepa), which is reasonably close to the 
experimentally determined value (i.e., 2.34, Table 4).
Assuming that the current PBPK model for LB is predictive, the 
PBPK model for LB may also be used to mimic in vivo DDI between LB and 
ATV by using the metabolic and transport kinetic parameters for LB obtained 
from in vitro studies. The observed and simulated LB concentration profiles 
for the plasma and liver are presented in Figs. 13A and 13B, and their 
pharmacokinetic parameters are summarized in Table 4. For the case of the 
Kp,liver value of LB with ATV, the predicted value (1.71) was similar to that 
based on an experimental determination (1.55) when the Ki,OATP value was 
used in the calculation.
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4. Discussion
The possibility of DDI occurring between LB and ATV was examined, 
considering the likelihood of the concurrent development of hyperlipidemia / 
T2DM (Ervin, 2009) and overlapping metabolic (CYP3A) / transport 
(rOATP1B2) pathways for the two drugs. No apparent DDI was found (Fig. 1 
and Table 1) between the two drugs in their respective systemic 
pharmacokinetics, even though interactions between LB and ATV were 
detected in vitro both at the metabolic level (Fig. 4B) and transport (Figs. 5C 
and 5D). Despite its high lipophilicity, the volume of distribution was limited 
for LB (i.e., 271 ± 20 mL/kg), likely because it extensively binds to plasma 
proteins. In addition, the reduction in Kp,liver for LB (i.e., from 2.34 to 1.55) by 
ATV did not appear to be significant in the total Vss, considering the fact that 
the contribution of the reduced distribution of LB to the liver would be 
approximately 27 mL/kg, which is relatively small for the Vss of 271 mL/kg. 
In other clinical DDI studies involving LB with metformin (i.e., T2DM agent), 
LB with warfarin (i.e., an anticoagulant with narrow therapeutic index), or LB 
with amlodipine (i.e., an anti-hypertensive agent) (Shin et al., 2012; Jung et 
al., 2015; Kim et al., 2015), no apparent changes in the systemic 
pharmacokinetics was found as well. In contrast, however, the liver 
concentration of LB was significantly decreased by the co-administration of 
ATV (Fig. 2 and Table 2). A concentration-dependent decrease was readily 
apparent for the Kp,liver of LB for different levels of steady state LB 
concentrations (Fig. 3) and the extent of liver distribution was determined. 
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These findings are the first indication of this ‘liver-specific’ DDI between LB 
and ATV in rats. Other tissue-specific DDIs have also been noted. A decrease 
in the concentration of metformin in the liver and kidney was reported, 
without any apparent change in the systemic pharmacokinetics, for the co-
administration of cimetidine or pyrimethamine: This tissue-specific change 
was mediated by the inhibition of mMATE1 (Ito et al., 2012; Shingaki et al., 
2015). In addition, an increase in the concentration of donepezil in the heart 
and brain was reported, without any appreciable change in the systemic 
pharmacokinetics, after the co-administration of cilostazol, probably by the 
inhibition of the breast cancer resistance protein (Takeuchi et al., 2016).
The metabolic rate of LB was also decreased by ATV (Fig. 4), 
although the Ki,MIC for ATV (i.e., 15.0 μM, unbound concentration) as 
estimated from in vitro data was relatively high. Since the estimated unbound 
liver concentration of ATV in vivo would be close to 71.8 nM (calculated from 
the observed Cmax,liver of ATV when ATV is administered with LB in the tissue 
study by multiplying   ,      ,      ,     ,   )⁄ , the maximum concentration 
of free ATV in the liver (i.e., 1.27 μM) would still be approximately 12-fold 
lower than the calculated Ki,MIC value, even if all ATV in the plasma is present 
as the unbound form. Taken together, the hepatic metabolism of LB is not 
likely to be significantly inhibited by the ATV dose administered in this study.
In addition, the reduced metabolic activity by ATV from in vitro studies did 
not appear to be consistent with in vivo observations in which a lower hepatic 
concentration of LB by the co-administration of ATV was found. Therefore, 
we did not pursue the mechanism responsible for the metabolic interaction 
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between LB and ATV in vitro any further.
It is now well established that rOATP1B2 is primarily expressed in 
the liver in rats and ATV is one of its representative substrates (Knauer et al., 
2010). These findings indicate that the transport of LB in rOATP1B2 
expressing cells had a Km,OATP of 2.06 ± 0.45 μM with a Ki,OATP by ATV of 
0.296 ± 0.174 μM (Fig. 5A and 5C). The uptake of LB was found to be 
saturable and inhibited by ATV with Ki,hepa values of 0.875 ± 0.739 μM in the 
study involving isolated rat hepatocytes. Collectively, our observations 
suggest that the distribution of LB to the liver is mediated by hepatic uptake 
transporter(s), such as rOATP1B2, and the liver distribution of LB is inhibited 
by the co-administration of ATV, a rOATP1B2 substrate. As confirmation the 
rOATP1B2 is involved in liver specific DDI, we found that the Kp,liver of ATV 
declined from 97.8 to 65.4 by the co-administration of LB (Table 2).
Based on in vitro studies, LB appeared to be transported to the liver 
via passive diffusion and carrier-mediated transport(s). Assuming that a 
similar process occurs in vivo, evaluating the Kp,liver,pass of LB, representing the 
liver-to-plasma concentration ratio for LB by passive diffusion only, was 
necessary. We used the method of Rogers and Rowland (Rodgers and 
Rowland, 2006) for this (i.e., 0.794 for LB). Interestingly, the current value 
was comparable to Kp,liver measured from the IV infusion study at the highest 
dose of LB with ATV (i.e., 0.714 ± 0.184; Fig. 3B). The ATV plasma 
concentration was found to be approximately 4.8 µM and the estimated Ki,OATP
value by ATV approximately 0.3 μM in rOATP1B2 expressing cells. 
Therefore, carrier-mediated transport by rOATP1B2 appears to be fully 
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inhibited under the above conditions. In subsequent calculations, the 
computational estimate was assumed to be adequate and was used.
It has been reported that “albumin-mediated uptake mechanism(s)” in 
hepatocytes may occur for highly bound drugs such as LB and ATV (Poulin et 
al., 2016). The calculated fu,plasma,surf value for ATV was found to be 
approximately 5-fold higher than fu,plasma for ATV (i.e., fu,plasma,surf and fu,plasma for 
ATV were 0.280 and 0.0567, respectively), indicating that the potency of ATV 
for inhibiting the hepatic uptake of LB might be underestimated by as much 
as 5-fold if the fu,plasma of ATV is used instead of fu,plasma,surf of ATV (Poulin 
and Haddad, 2015). In this study, the simulation using fu,plasma,surf, instead of 
fu,plasma, yielded improved predictions (Supplemental Fig. 8).
The theoretical Kp,liver assuming LB without the co-administration of 
ATV was calculated to be 2.18 ± 0.09, comparable to the observed Kp,liver
value (i.e., 2.34). In addition, the estimated Kp,liver assuming LB was co-
administered with ATV was 1.71 ± 0.13, close to 1.55 under a similar in vivo
situation. Taken together, the simulated Kp,liver values for LB with or without 
ATV were found to be in reasonable agreement with the observed data. It is 
noteworthy that the kinetic calculation was primarily based on parameters 
obtained from in vitro studies using rOATP1B2 expressing cells. Therefore, 
the liver specific DDI between LB and ATV may due to the interaction of 
rOATP1B2 between the two drugs. Since rOATP1B2 is known to be 
functionally analogous to hOATP1B1 (Hagenbuch and Meier, 2003), a similar 
interaction (e.g., the lack of DDI in systemic exposure while the liver 
concentration for LB reduced by ATV) may occur between LB and ATV in 
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humans. This aspect of DDI involving LB and ATV warrants further 
investigation.
While LB was reported to be a PPARγ agonist, it possessed a strong 
affinity for PPARα (i.e., EC50 value of 0.02 μM) (Lee et al., 2007). It was 
reported that fenofibrate, a PPARα agonist, may improve insulin sensitivity, 
probably by interactions between the drug and its receptor, as shown in an 
animal model of diabetes and obesity (Koh et al., 2003). Interestingly, the 
effective dose of LB was significantly lower than that for rosiglitazone and 
pioglitazone [i.e., (in effective dose) LB, 0.5 mg/day; rosiglitazone, 2-8 
mg/day; pioglitazone, 15-45 mg/day] (Balfour and Plosker, 1999; Hauner, 
2002; Park et al., 2014). Therefore, it is possible that the higher potency of LB 
may be partly mediated by the interaction of LB with PPARα. Assuming this, 
the liver may be regarded as an additional site of action for LB, since the 
receptor is highly expressed in the liver (Braissant et al., 1996). Considering 
that the co-administration of LB and ATV led to a liver-specific decrease in 
the distribution of the two drugs, efficacy could be affected for the two drugs. 
In particular, since the liver is likely to be closely linked to the 
pharmacological activity of the drugs (i.e., the primary site of action for ATV 
and potentially the secondary site for LB), additional studies may be 
necessary to confirm the impact of the liver specific DDI on the 
pharmacological activity.
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5. Conclusion
The co-administration of ATV led to a significant decrease in the liver 
concentration of LB with no appreciable change in its plasma concentration in 
rats. Metabolic interactions between LB and ATV appeared to cause only 
minor kinetic changes and is not likely to account for the liver-specific 
decrease in LB levels in vivo. LB was found to be a substrate for rOATP1B2 
and carrier-mediated transport was inhibited by ATV, even at low 
concentrations. The transport variables obtained from in vitro studies and the
PBPK model assuming a carrier-mediated transport process in distribution to 
the liver were adequate for mimicking the in vivo pharmacokinetics of LB 
with or without the co-administration of ATV. Considering that LB and ATV 
might be used in combination, the liver specific DDI caused by the 
combination found in this study may be therapeutically relevant.
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6. Theoretical
In this study, the pharmacokinetics of LB was assumed to be adequately 
explained by taking 9 typical tissues into consideration. Thus, the distribution 
of LB to the lung compartment may be expressed as:
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  ,  
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where VLU is the volume of lung; CLU is the drug concentration in the lung; 
QCO is the cardiac output; CVB is the venous blood concentration of drug; B/P 
is the blood-to-plasma concentration ratio; and Kp,LU is the tissue-to-plasma 
partition coefficient of the lung.
In the venous blood compartment:
    ∙
    
  
=     ∙
    ∙  / 
  ,  
+     ∙
    ∙  / 
  ,  
+   
∙
    ∙  / 
  ,  
+    ∙
    ∙  / 
  ,  
+     ∙
    ∙  / 
  ,  
+    ∙
    ∙  / 
  ,  
+     ∙
    ∙  / 
  ,  
+    
∙
    ∙  / 
  ,  
+     ∙
    ∙  / 
  ,  
−     ∙    
+    	    
(2)
where VVB is the volume of the venous blood; QAD, QBR, QHE, QKI, QMU, QLI, 
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QSP, QGU, and QRE are the blood flows to the adipose, brain, heart, kidney, 
muscle, liver, spleen, gut, and the rest of body, respectively; CAD, CBR, CHE, 
CKI, CMU, CLI, CSP, CGU, and CRE are the drug concentration of adipose, brain, 
heart, kidney, muscle, liver, spleen, gut, and the rest of body, respectively; 
Kp,AD, Kp,BR, Kp,HE, Kp,KI, Kp,MU, Kp,LI, Kp,SP, Kp,GU, and Kp,RE are the tissue-to-
plasma partition coefficient of the adipose, brain, heart, kidney, muscle, liver, 
spleen, gut, and the rest of the body, respectively. Since the kinetics of the rest 
of the body were negligible for the pharmacokinetics of both LB and ATV 
(i.e., Vss calculated by Øie-Tozer equation for the 9 major tissues and plasma 
accounted for 89.4% and 167% of Vss based on the moment analysis of the 
plasma concentration profiles of LB and ATV, respectively) (Øie and Tozer, 
1979), the Kp,RE value was arbitrarily set to be 0.001. Dose rate refers the
dosing rate of the LB and/or ATV.
In the arterial blood compartment of LB and ATV:
    ∙
    
  
=     ∙ (
    ∙  / 
  ,  
−    )
(3)
where VAB is the arterial blood volume; CAB and CAP are the drug 
concentration in arterial blood and plasma, respectively; In our previous 
report (Lee et al., 2015b), the excretion of LB to the bile was found to be 
negligible (i.e., 0.31%-0.37% of total dose of LB). Therefore we assumed that 
the elimination of LB and ATV is mainly by hepatic metabolism (Lennernas, 
2003; Lee et al., 2015b).
In the liver compartment of LB and ATV:
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Metabolism of LB without ATV:
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Metabolism of LB with ATV:
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Distribution to the liver of LB without ATV:
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Distribution to the liver of LB with ATV:
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In the liver compartment of ATV:
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where VLI is the liver volume; CLu,int is the unbound intrinsic clearance;
Vmax,MIC is the maximal rate in the microsomal incubation; Km,MIC is the 
Michaelis-Menten constant in the microsomal incubation; LW, MPPGL, and 
HPGL were the liver weight (9 g), microsomal protein per gram liver (46 
mg/g liver), and hepatocellularity per gram liver (108 × 106 hepatocytes/g 
liver). For scaling the kinetic parameters from in vitro experiments to an in 
vivo situation, the Simcyp® default values were used.
Kp,LI,pass is the tissue-to-plasma partition coefficient of the liver with 
when drug transport into and out of tissue is mediated only by symmetric 
passive diffusion (i.e., theoretically the ratio of the free fraction in plasma to 
that in liver; fu,plasma,surf / fu,liver), where fu,plasma,surf is the unbound fraction of drug
at cell surface in plasma (Poulin et al., 2016), respectively. Kp,liver,pass was 
calculated using mechanistic in silico prediction methods (Rodgers and 
Rowland, 2006) within Simcyp®, and fu,plasma,surf was calculated using the eq. 
10 (Poulin et al., 2012; Yun and Edginton, 2013; Poulin et al., 2016):
  ,      ,     =
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          ,      
          ,     
1 + (    − 1) ∙
          ,      
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where PLR is the plasma to tissue concentration ratio of extracellular binding 
proteins and the value for the liver was 13.3 (Poulin et al., 2012). The 
funionized,plasma and funionized,cells are the fraction of uninonized drugs in plasma and 
cells. The values of funionized,plasma and funionized,cells were calculated using the pKa
value(s) of each drug, and the physiological pH values on both sides of the 
membrane (e.g., 7.1 for liver and 7.4 for plasma) based on Hendersone-
Hasselbalch equations (Yun and Edginton, 2013; Poulin, 2015).
In other tissue compartments:
        ∙
        
  
=         ∙      −
        ∙  / 
  ,      
 
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where Vtissue, Ctissue, and Kp,tissue are the tissue volume, the drug concentration in 
the tissue, and the tissue-to-plasma partition coefficient, respectively.
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Table 1 Pharmacokinetic parameters for LB and ATV after an IV bolus 
administration of LB (1 mg/kg dose) with and without the co-administration 
of 5 mg/kg ATV to rats, and after IV bolus administration of 5 mg/kg dose of 
ATV with and without 1 mg/kg dose of LB to rats, respectively.
Parameter
LB ATV
LB LB + ATV ATV ATV + LB
AUCInf (µg ∙ min/mL) 422 ± 55 382 ± 85 57.5 ± 26.6 52.1 ± 16.4
t1/2 (min) 99.1 ± 4.7 86.4 ± 10.8 22.3 ± 0.9 22.3 ± 1.8
MRT (min) 117 ± 18 111 ± 19 16.2 ± 1.9 16.3 ± 1.4
CL (mL/min/kg) 2.34 ± 0.37 2.67 ± 0.63 102 ± 41 103 ± 33
Vss (mL/kg) 271 ± 20 289 ± 20 1610 ± 600 1670 ± 537
The data are expressed as the mean ± S.D. of quadruplicate runs for LB and 
pentaplicate runs for ATV.
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Table 2 Tissue-to-plasma partition coefficient (Kp) for LB and ATV in rats and 
the volume of blood trapped in rat tissues.
LB ATV Volume of trapped 
blood
in tissues (mL/g tissue)
Tissue LB
LB + 
ATV
ATV
ATV + 
LB
Lungs 0.240 0.290 1.34 1.96 0.283 ± 0.035
Adipose 0.216 0.216 0.158 0.335 0.0309 ± 0.0063 
Brain 0.0252 0.0296 0.0349 0.0270 0.0176 ± 0.0014
Heart 0.343 0.410 0.400 0.396 0.139 ± 0.004
Kidneys 0.406 0.478 2.51 3.28 0.209 ± 0.083
Muscle 0.109 0.170 0.480 0.586 0.0387 ± 0.0082
Liver 2.34 1.55 97.8 65.4 0.105 ± 0.026
Spleen 0.165 0.170 0.884 0.461 0.0430 ± 0.0209
Gut 0.234 0.196 125 64.1 0.107 ± 0.017
The Kp values are obtained from triplicate runs. The volumes of trapped blood 
in the tissue are expressed as the mean ± S.D. of triplicate runs.  
Kp,tissue = (AUCinf,tissue / AUCinf,plasma)
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Table 3 Summary of kinetic parameters for LB and ATV used in PBPK 
calculation.
Parameter LB ATV Reference/comment
Molecular 
weight (g/mol)
480.5 558.6
Drug bank. 
http://www.drugbank.ca
Log P 4.3 5.7
ChemAxon. 
https://www.chemaxon.com
Compound
type
Zwitterions
Monoprotic 
acid
pKa (acid) 7.61 4.3 ChemAxon. 
https://www.chemaxon.compKa (base) 3.96
fu,plasma 0.00267 0.0567
Determineda, Ref. (Watanabe et 
al., 2010) b
B/P 0.636 1.2
Determineda, Ref. (Watanabe et 
al., 2010) b
Distribution
Kp
0.0252-
2.34
0.0270-97.8 Determined
Distribution to 
liver
PS
(µL/min/106 
cells)
21.0 ± 6.0 Determined
Jmax,hepa 637 ± 384 Determined
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(pmol/min/106 
cells)
Km,hepa (µM) 16.3 ± 10.0 Determined
Elimination 
Vmax,MIC 
(pmol/min/mg 
protein)
996 Determined
Km,MIC (µM) 4.37 Determined
fu,MIC 0.479 0.557
Determineda, Ref. (Watanabe et 
al., 2010) b
CLu,int
(mL/min)
1530
Calculated using the CL value 
of ATV from IV bolus study 
with LB co-administration
Inhibition
Ki,MIC (µM) 27.0 Determined
Ki,hepa (µM)
0.875 ± 
0.739
Determined
Ki,OATP (µM)
0.296 ± 
0.174
Determined
fu,BSA
0.111-
0.447
0.588 Determined
a for LB
B for ATV
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Table 4 Observed and simulated pharmacokinetic parameters for LB for an IV
bolus administration of 1 mg/kg dose of LB alone and 1 mg/kg dose of LB 
with 5 mg/kg dose of ATV to rats.
Observed Simulated
Parameter LB LB + ATV LB LB + ATV
AUCinf,plasma (µg ∙ min/mL) 435 509 493 ± 0.08 492 ± 29
a
AUCinf,liver (µg ∙ min/mL) 1020 789 1070 ± 46 842 ± 68
a
Kp,liver 2.34 1.55 2.18 ± 0.09 1.71 ± 0.13
a
The simulated data are expressed as the mean ± S.D. of three virtual rats from 
in vitro experiments in triplicate runs.
a Values were determined using Ki,OATP values. Kp,liver values were 1.83 ± 0.22
using Ki,hepa values.
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Figure 1 Uptake of estradiol-17β-glucuronide (1% of [3H] radiolabeled 
compound in 1 μM) in the mock- / rOATP1B2-MDCK cells. In this study, 
mock cells were used as control. The data are expressed as the mean ± S.D. of 
triplicate runs.
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Figure 2 Incubation time-uptake rate curve for LB (10 μM) in Mock (●)-  / 
rOATP1B2 (○)-expressing MDCK cells. The data are expressed as the mean ± 
S.D. of triplicate runs.
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Figure 3 The inhibitory effect of the DMSO content (%) in the transport 
medium on the transport of LB (1 μM) into MDCK cells. One-way ANOVA 
indicated that DMSO up to 2% in the medium had no appreciable effect on 
the transport of LB into cells (p > 0.05). In this study, 0.1% DMSO group was 
used as control. The data are expressed as the mean ± S.D. of quadruplicate 
runs.
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Figure 4 (A) The effect of the BSA content (%) in the rinsing solution on the 
protein concentration in the cell lysate. One-way ANOVA indicated that BSA 
up to 3% in the solution had no appreciable effect on the protein concentration 
in the cell lysate (p > 0.05). (B) The effect of the BSA content (%) in the 
rinsing solution for the minimization of the non-specific binding on the 
experimental apparatus and/or on cell surface. One-way ANOVA indicated 
that the relative detected amounts of LB associated with rOATP1B2 cells 
were not statistically different (p > 0.05) for BSA concentrations ranging from 
0.1% to 10% in the rinsing solution. In this study, 0% BSA groups were both 
used as control. The data are expressed as the mean ± S.D. of quadru- (A) / 
tri- (B) plicate runs, respectively.
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Figure 5 The inhibitory effect of the DMSO content (%) in the transport 
medium (i.e., KHB) on transport of LB (3 μM) into isolated rat hepatocytes at 
37°C. Student t test indicated that 10% DMSO in the medium had no 
appreciable effect on transport of LB into hepatocytes (p > 0.05). In this study, 
2% DMSO group was used as control. The data are expressed as the mean ± 
S.D. of triplicate runs.
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Figure 6 (A) Incubation time-uptake rate curves for LB (10 μM) in isolated 
rat hepatocytes at 4°C (●) and 37°C (○). The data are expressed as the mean ± 
S.D. of triplicate runs.
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Figure 7 Observed and simulated tissues and plasma concentration–time 
profiles for LB (A) after IV bolus administration of 1 mg/kg dose of LB and 
ATV (B) after IV bolus administration of 5 mg/kg dose of ATV with co-
administration of 1 mg/kg dose of LB to rats. Black circles, solid line, and 
dashed line (almost superimposed to the solid line) represent the observed, 
simulated (Simcyp®), and simulated (Berkeley Madonna™) concentration of 
LB (A) and ATV (B), respectively. The used input parameters for LB and ATV 
are summarized in Table 3 including the Kp,liver value from in vivo study. The 
black circles represent the mean ± S.D. of triplicate runs.
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Figure 8 (A) Temporal profiles for the plasma concentration of LB after an IV 
bolus administration of 1 mg/kg dose of LB alone (●) and 1 mg/kg dose of LB 
with 5 mg/kg dose of ATV (○) to rats. (B) Temporal profiles for the plasma 
concentration of ATV after an IV bolus administration of 5 mg/kg dose of 
ATV alone (●) and 5 mg/kg dose of ATV with 1 mg/kg dose of LB (○) to rats. 
The data are expressed as the mean ± S.D. of quadruplicate runs in A and 
pentaplicate runs in B.
0 120 240 360 480
10
100
1000
10000
Time (min)
P
la
s
m
a
c
o
n
c
e
n
tr
a
ti
o
n
o
f
L
B
(n
g
/m
L
)
0 30 60 90 120
1
10
100
1000
10000
Time (min)
P
la
s
m
a
c
o
n
c
e
n
tr
a
ti
o
n
o
f
A
T
V
(n
g
/m
L
)
A B
66
Figure 9 (A) Temporal profiles for plasma and tissue concentration of LB 
after IV bolus administration of 1 mg/kg dose of LB alone (●) and 1 mg/kg 
dose of LB with 5 mg/kg dose of ATV (○) to rats. (B) Temporal profiles for 
the plasma and tissue concentration of ATV after IV bolus administration of 5 
mg/kg dose of ATV alone (p) and 5 mg/kg dose of ATV with 1 mg/kg dose of 
LB (△) to rats. The data are expressed as the mean ± S.D. of triplicate runs.
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Figure 10 (A) Temporal profiles for the plasma concentration of LB after an 
IV infusion at dosing rates of 50 (● for LB alone and ○ for LB with ATV 10 
μg/min), 250 (p for LB alone and △ for LB with ATV 10 μg/min), and 1000 
(◆ for LB alone and ◇ for LB with ATV 10 μg/min) ng/min. (B) Liver-to-
plasma concentration ratio of LB at 6 h after an IV infusion at the dosing rates 
of 50, 250, and 1000 ng/min to rats. Asterisks on black circle indicate 
statistical differences (∗∗p < 0.01 and ∗∗∗p < 0.001) from the lowest LB dose 
(i.e., by one-way ANOVA, followed by Tukey’s post hoc test), and asterisks 
under the white circle indicate statistical differences (∗p < 0.05 and ∗∗p < 
0.01) from the control (i.e., the absence of ATV) by unpaired Student’s t test. 
The data are expressed as the mean ± S.D. of quadruplicate runs.
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Figure 11 (A) The concentration-metabolic reaction rate curve for LB in an 
incubation with rat liver microsomes. The solid line was generated by the 
best-fit parameters obtained from the nonlinear regression analysis based on 
Michaelis–Menten kinetics (eq. 2). The inset represents an Eadie–Hosftee plot 
of the concentration-metabolic reaction rate curve. The solid line indicates the 
linearly regressed line of the data. (B) The inhibitory effect of ATV on the 
metabolic reaction rate of LB (5 μM) for an incubation with rat liver 
microsomes. The solid line was generated by the best-fit parameters obtained 
from the nonlinear regression analysis based on eq. 3. Each symbol represents 
the mean ± S.D. of triplicate runs.
0 10 20 30 40 50
0
200
400
600
800
1000
LB concentration (µM)
M
e
ta
b
o
lic
ra
te
o
f
L
B
(p
m
o
l/m
in
/m
g
p
ro
te
in
)
1 10 100
0
200
400
600
ATV concentration (µM)
M
e
ta
b
o
lic
ra
te
o
f
L
B
(p
m
o
l/m
in
/m
g
p
ro
te
in
)
0.00 0.05 0.10 0.15 0.20 0.25
0
500
1000
V/LB
V
A B
69
Figure 12 (A) The unbound concentration-uptake rate curve for LB in Mock-
MDCK cells (●) and rOATP1B2-expressing MDCK cells (○). (B) Unbound 
concentration-uptake rate curve for LB in rat hepatocytes at 4°C (●) and 37°C
(○). The solid lines were generated by the best-fit parameters obtained from 
the simultaneous nonlinear regression analysis based on eq. 4 and eq. 5, 
respectively. The inhibitory effect of ATV on the uptake of LB (C) in 
rOATP1B2-expressing MDCK cells, and (D) rat hepatocytes. The solid line 
was generated by the best-fit parameters obtained from the nonlinear 
regression analysis based on eq. 6, respectively. Asterisks indicate statistical 
difference (∗∗p < 0.01 and ∗∗∗p < 0.001) from the control group (i.e., without 
ATV) by one-way ANOVA, followed by Dunnett’s post hoc test. Each symbol 
represents the mean ± S.D. of triplicate runs in A, B, and C, and octuplicate 
runs in D.
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Figure 13 (A) Observed and simulated plasma concentration–time profiles for 
LB after IV bolus administration of 1 mg/kg dose of LB with or without 5 
mg/kg dose of ATV to rats. Black circles, solid line, white circles, and dashed 
line represent the observed (LB alone), simulated (LB alone), observed (LB 
with ATV), and simulated (LB with ATV, with the Ki,OATP value) plasma 
concentration of LB, respectively. (B) Observed and simulated liver 
concentration–time profiles for LB after IV bolus administration of 1 mg/kg 
dose of LB with or without 5 mg/kg dose of ATV to rats. Black circles, solid 
line, white circles, and dashed line represent the observed (LB alone), 
simulated (LB alone), observed (LB with ATV), and simulated (LB with ATV, 
with the Ki,OATP value) liver concentration of LB, respectively. Symbols 
represent the mean ± S.D. of triplicate runs. The input parameters for LB and 
ATV are summarized in Table 3.
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Figure 14 Observed and simulated liver concentration–time profiles for LB 
after IV bolus administration of 1 mg/kg with 5 mg/kg dose of ATV to rats.
Black circles, solid line, and dashed line represent the observed, simulated 
(using fu,plasma of ATV), and simulated (using fu,plasma,surf of ATV) liver 
concentration of LB, respectively. The black circles represent the mean ± S.D. 
of triplicate runs.
0 60 120 180 240
100
1000
10000
L
iv
e
r
c
o
n
c
e
n
tr
a
ti
o
n
o
f
L
B
(n
g
/m
L
)
Time (min)
72
국문초록
본 연구는 peroxisome proliferator-activated receptor gamma 
(PPARγ) 활성제로 개발된, lobeglitazone(LB)과 HMG-CoA reductase 
inhibitor (Statins)로 잘 알려진, atorvastatin (ATV)과의 약물 상호 작용
에 관한 연구이다. 본 연구실에서의 선행 연구에 의하면 CYP 효소
들과 hOATP1B1 은 LB의 약물 동태학적 특성과 관련이 있는 것으
로 보인다. ATV는 CYP3A와 hOATP1B1의 기질로 잘 알려져 있고, 
대사성 질환 (고혈압, 고지혈증, 당뇨병 등)을 가지는 환자군에게
LB와 함께 처방 될 가능성이 있다. 하지만, 아직까지 LB와 ATV의
약물 상호 작용에 대한 연구는 보고된 바가 없다. 그리하여, 랫드의
혈장과 9개의 주요 조직들에서 LB와 ATV의 약물 상호 작용 여부를
관찰하였다.
정맥을 통해서 LB와 ATV를 함께 투여하였을 때, LB의 전신
클리어런스 (CL)는 2.67 ± 0.63 mL/min/kg 이었고, 정상상태의 분포 용
적 (Vss )은 289 ± 20 mL/kg 이었다. 이 값은 같은 방법으로 LB를 단
73
독으로 투여하였을 때의 값 (CL, 2.34 ± 0.37 mL/min/kg; Vss, 271 ± 20 
mL/kg)과 각각 통계학적으로 유의미하게 다르지 않았다. 이 결과에
의하면 혈장 수준에서는 LB와 ATV의 약물 상호 작용의 가능성이
낮다고 볼 수 있다. 조직 분포 실험의 결과에 따르면, LB를 단독으
로 정맥 투여 하였을 때의 조직분배계수 (Kp) 값은 0.0252 (뇌) 에서
2.34 (간) 의 값을 가졌으며, LB와 ATV를 병용 투여 하였을 때의 LB
의 Kp 값은 0.0296 (뇌)에서 1.55 (간)의 값을 가졌다. 다른 장기와는
달리, 가장 많이 분포되는 간의 Kp 값이 감소한 것을 관찰하고, LB
(혹은 ATV와 함께)를 정맥으로 infusion하여 정상상태에서의 혈장과
간 중 농도를 측정하였다. LB 단독 투여군에서의 Kp 값은 3.14 ± 0.46 
(at 50 ng/min), 1.55 ± 0.52 (at 250 ng/min), 0.959 ± 0.259 (at 1000 ng/min)
이었고, LB의 투여 농도가 높아짐에 따라 유의적으로 감소함을 알
수 있었다 (p < 0.001, by ANOVA). 또한, 이 값들은 ATV 를 고농도
(10 μg/min)로 병용 투여 하였을 때 1.38 ± 0.39 (at 50 ng/min), 0.701 ± 
0.013 (at 250 ng/min), 0.714 ± 0.184 (at 1000 ng/min)로 변했으며, 이는
ATV가 LB의 간으로의 수송을 저해한 결과로 사료되었다. rOATP1B2
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가 과발현된 MDCK세포주와 분리된 간세포에서의 in vitro 실험에서
도 in vivo 실험결과 (ATV가 LB의 간으로의 수송을 저해함)와 일치
하는 결과를 도출할 수 있었다.
약물 상호 작용을 정량적으로 알아보기 위해서 PBPK 모델
링 방법을 이용하였다. 우선, in vitro실험에서 얻은 각종 파라미터들
(Km, Vmax, Ki and PS)을 적합한 PBPK model에 적용하여 시뮬레이션을
한 결과는 LB와 ATV의 in vivo 를 잘 예측하였다. 특히, LB의 간 중
농도가 ATV의 투여에 의해서 저해되는 것을 PBPK 모델링을 통해
서 입증함으로써, 약물 상호 작용을 성공적으로 정량함에 더해서
rOATP1B2의 저해에 의한 약물 상호 작용을 뒷받침하였다. 
이상의 결과를 종합해보면, LB 와 ATV 의 병용 투여에 의해서
LB 의 혈장 수준에서는 약물 상호 작용이 관찰되지 않았으나
rOATP1B2 를 매개로 하는 간으로의 LB 수송을 저해함으로써 간 중
농도를 감소 시키는 약물 상호 작용을 관찰하였다. 임상적으로
LB 와 ATV 는 병용할 가능성이 있기 때문에 본 연구를 임상에도
적용하여 추가적인 연구가 필요하다고 사료된다.
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